Opinion

Video

Monitoring Strategies for Managing ADC Toxicities in mBC

Author(s):

Heather Moore, BCOP, CPP, PharmD, Jodi Taraba, PharmD, MS, BCOP

Panelists discuss how pharmacists should monitor neutropenia, diarrhea, and mucositis from sacituzumab govitecan (SG); interstitial lung disease (ILD) and neutropenia from trastuzumab deruxtecan (T-DXd); and neutropenia and ILD from datopotamab deruxtecan (Dato-DXd). Proactive management is essential for patient safety.

Video content above has been prompted by the following:

  • Toxicity management is critical for patients on antibody-drug conjugates (ADCs). What are the most important ADC-related AEs that pharmacists should monitor (eg, neutropenia, diarrhea, ILD, mucositis) for T-DXd, SG, and Dato-DXd?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
2 KOLs are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
Computer Screen in Hospital Radiology Room: Woman Standing Undergoing Mammography Screening Procedure. Screen Showing the Mammogram Scans of Dense Breast Tissues - Image credit: Gorodenkoff | stock.adobe.com
September 3rd 2025

Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer

Kennedy Ferruggia, Assistant Editor
pharmacy focus oncology edition
September 3rd 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
In the hospital, the patient undergoes a screening procedure for a mammogram, which is performed by a mammogram. A modern technologically advanced clinic with professional doctors. Image Credit: Valerii Apetroaiei | stock.adobe.com
September 3rd 2025

Suppression of JNK Pathway Drives Resistance to Endocrine and CDK4/6 Therapy in ER-Positive Breast Cancer

Danielle Valletti, Assistant Editor
Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations
September 3rd 2025

Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations

Alexandra Gerlach, Associate Editor
Selection Considerations for Abemaciclib Versus Ribociclib in Early HR+/HER2- Breast Cancer: Efficacy, Safety, and Long-Term Outcomes
September 3rd 2025

Selection Considerations for Abemaciclib Versus Ribociclib in Early HR+/HER2- Breast Cancer: Efficacy, Safety, and Long-Term Outcomes

Benjamin Gibson, PharmD, PAHM
Vials and flasks in lush green foliage and chemical compounds background, science and medicine, natural remedies... | Image Credit: Nikolai | stock.adobe.com
September 3rd 2025

Exploring Natural Compounds: Prunus Armeniaca, Bee Venom, and Bioactives in Breast Cancer Therapy

Danielle Valletti, Assistant Editor
© 2025 MJH Life Sciences

All rights reserved.